Gracell Biotechnologies Inc GRCL

NAS: GRCL | ISIN: US38406L1035   21/02/2024
10,25 USD (+0,05%)
(+0,05%)   21/02/2024

6 september 2023 · Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 2023 International Myeloma Society Annual Meeting · Persbericht

7 augustus 2023 · Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors · Persbericht

7 augustus 2023 · Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors · Persbericht

3 juni 2023 · Gracell Biotechnologies Presents Updated Data of Deep and Durable Responses for FasTCAR-T GC012F in Relapsed/Refractory Multiple Myeloma at 2023 ASCO Annual Meeting · Persbericht

15 mei 2023 · Gracell Biotechnologies Initiates Investigational Study Evaluating GC012F for Treatment of Refractory Systemic Lupus Erythematosus (SLE) · Persbericht

11 mei 2023 · Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in RRMM and B-NHL and Donor-Derived CAR-T GC007g in B-ALL at EHA2023 Congress · Persbericht

26 april 2023 · Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F at 2023 ASCO Annual Meeting · Persbericht

28 februari 2023 · Gracell Biotechnologies to Participate in Oppenheimer 33rd Annual Healthcare Conference · Persbericht

27 februari 2023 · Gracell Biotechnologies to Report Fourth Quarter 2022 Financials on Monday, March 13, 2023 · Persbericht

13 februari 2023 · Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma · Persbericht

3 februari 2023 · Gracell Biotechnologies Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Relapsed/Refractory Multiple Myeloma · Persbericht

11 december 2022 · Gracell Biotechnologies Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response Rate · Persbericht

23 november 2022 · Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences · Persbericht

16 november 2022 · Gracell Biotechnologies Wins 2022 Fierce Life Sciences Innovation Award · Persbericht

3 november 2022 · Gracell Biotechnologies to Present First Clinical Data of FasTCAR-T GC012F for Newly Diagnosed Multiple Myeloma at 64th American Society of Hematology Annual Meeting & Exposition · Persbericht

31 oktober 2022 · Gracell Biotechnologies to Report Third Quarter 2022 Financials on Monday, November 14, 2022 · Persbericht

24 oktober 2022 · Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences · Persbericht

17 oktober 2022 · Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating GC007g for Treatment of B-cell Acute Lymphoblastic Leukemia · Persbericht

14 september 2022 · Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences · Persbericht

29 augustus 2022 · Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences · Persbericht

Mijn selecties